Several studies underscore a versatile role of the IL-33/T2-IL1RAcP pathway in the tumor microenvironment and tumorigenesis [20,29], thus making these proteins attractive therapeutic targets and potential biomarkers in MCC. The gene discussed is IL33; the disease is neoplasm.